Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Author(s): Jacob Sands, MD¹; Myung-Ju Ahn, MD¹; Aaron Lisberg, MD^1,2; Byoung Chul Cho, MD, PhD^1,3; George Blumenschein Jr, MD^1,4; Elaine Shum, MD^1,5; Elvire Pons Tostivint, MD, PhD^1,6; Yasushi Goto, MD, PhD^1,7; Kiyotaka Yoh, MD⁸; Rebecca Heist, MD, MPH⁹; Junichi Shimizu, MD, PhD¹⁰; Jong-Seok Lee, MD, PhD¹¹; Paul Baas, MD, PhD^1,12; David Planchard, MD, PhD^1,13,14; Maurice Pérol, MD^1,15; Enriqueta Felip, MD, PhD^1,16; Wu-Chou Su, MD^1,17; Hong Zebger-Gong, MD, PhD¹⁸; Lan Lan, PhD¹⁹; Chelsea Liu, PhD¹⁹; Paul Howarth, MD¹⁹; Rachel Chiaverelli, PhD¹⁹; Luis Paz-Ares, MD, PhD^1,20

Source: https://doi.org/10.1200/JCO-24-01349

Dr. Maen Hussein's Thoughts

Dato showed a confirmed overall response rate (ORR) of 42.7% with a complete response (CR) of 4.3%. The median duration of response was 7.0 months, with a disease control rate of 86.3% and a median overall survival (OS) of 15.6 months. This could be another option for EGFR mutant patients who had multiple lines of therapy.

PURPOSE

Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety and clinical activity of Dato-DXd in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy.

PATIENTS AND METHODS

Patients received Dato-DXd 6 mg/kg once every 3 weeks. The primary end point was objective response rate (ORR) by blinded independent central review. Secondary end points included duration of response (DOR), safety, tolerability, and survival.

RESULTS

Among 137 patients who received at least 1 dose of Dato-DXd, 71.5% received at least three lines of prior therapies for advanced/metastatic disease. Overall, 56.9% had EGFR mutations and 24.8% had ALK rearrangements. Median treatment duration was 4.4 months (range, 0.7-20.6). The confirmed ORR was 35.8% (95% CI, 27.8 to 44.4) overall, and 43.6% (95% CI, 32.4 to 55.3) and 23.5% (95% CI, 10.7 to 41.2) in those with EGFR mutations and ALK rearrangements, respectively. The median DOR was 7.0 months (95% CI, 4.2 to 9.8), and the overall disease control rate was 78.8% (95% CI, 71.0 to 85.3). Grade ≥3 treatment-related adverse events (TRAEs) occurred in 28.5% of patients. The most common TRAE was stomatitis (preferred term; any grade: 56.2%; grade ≥3: 9.5%). Five (3.6%) patients experienced adjudicated treatment-related interstitial lung disease/pneumonitis, with 1 (0.7%) grade 5 event.

CONCLUSION

Encouraging and durable antitumor activity was observed with Dato-DXd in this heavily pretreated advanced/metastatic NSCLC population with actionable genomic alterations. The rate of treatment-related grade ≥3 toxicities was comparable with previous observations, and no new safety signals were observed.

Author Affiliations

¹Dana-Farber Cancer Institute, Boston, MA;²David Geffen School of Medicine at UCLA, Los Angeles, CA;³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea;⁴The University of Texas MD Anderson Cancer Center, Houston, TX;⁵NYU Langone Health Perlmutter Cancer Center, New York, NY;⁶University Hospital of Nantes, Nantes, France;⁷National Cancer Center Hospital, Tokyo, Japan;⁸National Cancer Center Hospital East, Kashiwa, Japan;⁹Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA;¹⁰Aichi Cancer Center Hospital, Aichi, Japan;¹¹Seoul National University Bundang Hospital, Seongnam, Republic of Korea;¹²The Netherlands Cancer Institute, The Leiden University Medical Center, Amsterdam, the Netherlands;¹³Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France;¹⁴Paris-Saclay University, Paris, France;¹⁵Centre Léon Bérard, Lyon, France;¹⁶Vall d’Hebron Hospital Campus, Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain;¹⁷National Cheng Kung University Hospital, Tainan, Taiwan;¹⁸Daiichi Sankyo Europe GmbH, Munich, Germany;¹⁹Daiichi Sankyo, Inc, Basking Ridge, NJ;²⁰Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Complutense University and Cibereronc, Madrid, Spain

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer

The phase III NeoADAURA trial evaluated neoadjuvant osimertinib (OSI) with or without platinum-based chemotherapy (CT) versus CT alone in resectable, EGFR-mutated stage II-IIIB non-small cell lung cancer (NSCLC). Both OSI+CT and OSI monotherapy significantly improved major pathologic response (MPR: 26% and 25% vs 2%), and 12-month event-free survival (EFS) rates were higher with OSI-containing regimens (OSI+CT 93%, OSI 95%, CT 83%). Nodal downstaging was also more frequent with OSI arms (53% vs 21%). Neoadjuvant OSI—with or without CT—looks like a real step forward for our EGFR-mutant NSCLC patients, especially given the robust pathologic responses and high rates of surgical completion.

Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma

This large, well-done study compared systematic mediastinal lymph node dissection (LND) versus no LND in patients with GGO-dominant invasive lung adenocarcinoma (CTR ≤0.5, ≤3 cm, cT1N0M0). Interim analysis of 302 patients showed no lymph node metastases in either arm, with both groups achieving 3-year disease-free survival (DFS) and overall survival (OS) of 100% at the time of analysis. The no LND arm had significantly shorter surgery duration (74 vs 109 min), less blood loss (44 vs 82 mL), shorter hospital stays (3.9 vs 4.5 days), and fewer grade ≥2 complications (3.3% vs 9.3%). Based on these findings, the trial was terminated early for nonmaleficence, and the authors recommend omitting systematic mediastinal LND in this population. In short, for carefully selected GGO-dominant lung adenocarcinoma, skipping mediastinal LND appears safe and spares patients’ unnecessary morbidity—this could be a real practice-changer for our early-stage, node-negative cases.

Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC

The phase 3 MARIPOSA trial compared amivantamab–lazertinib (Ami-Laz) to osimertinib (Osi) in untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC), showing a significant overall survival (OS) benefit for Ami-Laz (3-yr OS was 60% vs 51%). Median OS was not reached for Ami-Laz vs 36.7 months for Osi, with a projected >12-month median OS advantage. Ami-Laz also improved time to symptomatic progression (43.6 vs 29.3 months) and showed durable intracranial control, though grade ≥3 adverse events (AEs) were higher (80% vs 52%), notably skin, venous thromboembolism (VTE), and infusion reactions. In short, Ami-Laz is emerging as a new standard for first-line EGFRm NSCLC, but we’ll need to be proactive about managing its toxicity profile in clinic and whether this is superior or equivalent to Osi + chemo is currently unclear.

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib demonstrated a median progression-free survival (PFS) of 5.5 months compared to 3.8 months with docetaxel in patients with KRAS G12C-mutated tumors. Treatment-related adverse events occurred in 47% of patients receiving Adagrasib and 46% in the docetaxel group. In my experience, Adagrasib is also more tolerable, making it a favorable option for this patient population.

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

There was a 28% reduction in mortality. Patients who achieved a complete response (CR) or clearance of circulating tumor DNA (ctDNA) also experienced better outcomes.